Abstract: Coagulase-negative staphylococci (CNS) are a heterogenous group of Gram-positive cocci that are widespread commensals among mammalia. Unlike their coagulase-positive counterpart, Staphylococcus aureus, CNS produce few virulence patterns and normally refrain from invading tissue. Yet, not only can CNS cause infections in normal host tissue, but modern medicine has also seen their rise as opportunists that display adherence to medical device materials to produce a protective biofi lm. CNS have historically been more resistant to antimicrobials, including the β-lactam antibiotics, than S. aureus and some hospitals reveal rates of oxacillin resistance in CNS approaching 90%. Cross resistance to non-β-lactam agents has been a recurrent theme over the past 40 years in the CNS. Thus, there has been a pressing need for newer antimicrobial agents with good antistaphylococcal activity. Those new agents tend to have excellent antistaphylococcal activity include daptomycin, linezolid, oritavancin, telavancin, tigecycline, dalbavancin, new quinolones, and ceftibiprole, several of which have unique mechanisms of action. The MIC 90 for these new compounds typically ranges from 0.5-4 µg/mL. Staphylococcal biofi lm formation is quite common in CNS infections and markedly increases the MIC for most older antimicrobials. Several of the newer agents offer some promise of penetration of biofi lm to inhibit or kill adherent staphylococci. CNS will likely remain a major cause of infections in the modern age, evolve further antimicrobial resistance mechanisms, and require development of newer antimicrobials for curative therapy.
Introduction
The group of Gram-positive bacteria identifi ed as coagulase-negative staphylococci (CNS), usually harmless commensals, have become important, commonly isolated pathogens in clinical microbiology laboratories around the world (Kloos and Bannerman 1994; Cerca et al 2005; Arciola et al 2006; Bayram and Balci 2006; Caierão et al 2006; Widerström et al 2006) . Over the last several decades, infection with CNS has been characterized as related to "medical progress" (Rupp and Archer 1994) . Accordingly, CNS, as human pathogens, are usually associated with healthcare settings and occur in patients who are immunocompromised or harboring indwelling polymer or metallic devices (Bisno 1995) .
By 1985, there were 19 recognized species of CNS, 8 of which exhibited a possible association with human infection (Kloos and Jorgensen 1985) . At that time, the most commonly isolated of these pathogenic species were Staphylococcus epidermidis and S. haemolyticus. Typing of CNS in the late 1980s was primarily based on biochemical testing profi les such as the one proposed by Schleifer in 1975 (Kloos and Schleifer 1975) . This scheme used certain biochemical markers including novobiocin resistance; fermentation of: sucrose, fructose, galactose, ribose, lactose, turanose, melezitose, xylose, mannose, trehalose, mannitol, xylitol, and maltose; and phosphatase nitrate reduction and use of arginine. With character types defi ned through major and minor biochemical routes, a simplifi ed scheme emerged for speciating staphylococci of human origin (Kloos and Schleifer 1975) .
Other early speciation methods included antimicrobial susceptibility profi le typing, multilocus enzyme electrophoresis, and cellular fatty acid analysis (Birnbaum et al 1991) . Due to the intensive labor involved in all of these early typing schemes and because of the assumption of the low virulence of this group of organisms, most isolates with morphology of Gram-positive cocci in clusters and positive for catalase production without coagulase production were described simply as CNS. Clinical debate continued about the clinical or therapeutic utility of speciating CNS; nevertheless, evidence emerged suggesting that particular species of CNS may be associated with specifi c diseases, readdressing the question of a need for speciation (Kloos and Bannerman 1994) .
In the US, bacteremia due to unspeciated CNS have increased from 9% to 27% from 1980 27% from to 1989 27% from (Schaberg et al 1991 . Over the last decade, the numbers of CNS species have grown to total 32, with half of these species isolated from human tissue and blood samples (von Eiff et al 2002) . Consequently, development of commercial automated systems such as the Microscan Pos ID, Rapid Pos ID (Baxter Diagnostic Inc., MicroScan Division, West Sacramento, CA, USA), and VITEK (bioMérieux Vitek Inc., Hazelwood, MO, USA) have facilitated more rapid testing of staphylococci by using computer software to analyze combined biochemical and antibiotic susceptibility profi les (Kloos and George 1991; Hussain et al 1998; Caierão et al 2006) . These robotic systems scan incubated trays using fl uorimetric and photometric readings to record fl ouresence, turbidity, and colormetric signals which indicate relative growth in each well (Ligozzi et al 2002) .
Each automated system uses a unique set of biochemical tests and species parameters. Small differences in identifi cation methods, however, have the potential to cause inconsistencies in results when comparing one system's speciation of a microbial isolate to another (Perl et al 1994) . Moreover, automated systems can cause outright misidentifi cation even at the genus level. In one report, results from an automated typing system were compared to those of a 16s rRNA speciation for 19 clinical bacterial isolates (Ben-Ami et al 2005) . The automated system identifi ed all of the isolates as Kocuria, while the 16s rRNA sequence subsequently identifi ed all 19 isolates as CNS, 18 S. epidermidis and 1 S. hamolyticus; nevertheless, the automated identifi cation of CNS at the levels of species and subspecies presents potential value for clinical correlation and therapeutic intervention (Rupp and Archer 1994) . Other work recently presented suggests S. epidermidis isolates may be misidentifi ed even as S. auricularis, so it is clear that erroneous typing could delay appropriate and necessary therapeutic intervention (John et al 2006) .
Regardless of species specificity, treatment of CNS infection has become increasingly diffi cult due to the high prevalence of antibiotic-resistant strains. Widely used antibiotics including penicillins, particularly semi-synthetic penicillins, cephalosporins, macrolides, aminoglycosides, and tetracyclines, have proven to be ineffective in inhibiting several prevalent species of CNS, thus, augmenting the need for new and effective antimicrobials (Cerca et al 2005; Gaudioso de Allori et al 2006; Arciola et al 2006) . To add to the resistance problem, multi resistance in CNS, as in S. aureus, is carried out on a staphylococcal chromosome cassette (SCC) which almost always includes the mecA gene for resistance to semi-synthetic penicillins (SCCmec) (Hanssen et al 2004) . SCCmec resides in the chromosome as several cassette variants I-V.
CNS are ubiquitous in nature, residing on skin and mucous membranes (Costa et al 2004) . When exposed to medical devices, the CNS anchor themselves to a polymer surface via van der Waal's forces, hydrophobic interactions, and polarity, ultimately forming a thick biofi lm (Vuong et al 2003; Mack et al 2006) . Production of biofi lm reduces the organism's susceptibility to specifi c antimicrobials which (Cerca et al 2005) . In this paper we will review the general problem of antibiotic resistance in CNS and discuss the susceptibility and resistance, where data are available, for specifi c species. Additionally, in view of a recent expansion in new anti staphylococcal agents, we will address the susceptibility profi les of some of these newer agents.
Pre-1994 susceptibility literature
Antimicrobial susceptibility in CNS became an issue in the 1970s when these species were isolated as pathogens in prosthetic valve endocarditis infections of cerebrospinal fl uid shunt infections (Keys and Hewitt 1973; Shoenbaum et al 1975) . There were earlier harbingers that new resistance genes were emerging, specifi cally those whose products would inhibit the binding of semisynthetic penicillins, agents that had been developed to resist the effects of extracellular staphylococcal β-lactamases. Methicillin was the predominant semisynthetic penicillin used in early therapy so the term "methicillin resistance" became a generic term for resistance to β-lactam antibiotics based on the inability of these agents to bind to the new penicillin-binding protein product of mecA, PBP-2a (Sutherland and Rollison 1964; Bentley et al 1967) . During the 1970s it became clear that methicillin resistance was more prevalent in CNS (MRCNS) than in methicillin-resistant S. aureus (MRSA), an observation that continues to be true today.
During the 1970s and early 1980s, the problem of multiresistance in CNS was reported primarily in cases of device related infections particularly prosthetic valve endocarditis (Archer 1978) . In a group of S. epidermidis associated with device infections, 56% were resistant to methicillin and 70% were resistant to cefoxitin and cephardine (Archer 1978) . For the subsequent period through 1994, Archer and Climo have reviewed the literature (Archer and Climo 1994) in which they report an escalation of resistance for almost all antimicrobial classes excluding glycopeptides: β-lactams aminoglycosides, trimethoprim, rifampin, fl uoroquinolones, macrolides, and tetracyclines. Therefore, in this current paper we will review the post-1994 literature on the subject.
Post-1994 susceptibility literature
The trends in resistance in CNS over the last 13 years have continued to show escalation in the frequency and expression of resistance determinants. Resistance to β-lactam agents (methicillin resistance) has remained the foremost strain determinant. Strains of MRCNS are often linked to multiresistance, like their MRSA counterparts, thus presenting an ongoing therapeutic challenge. The discovery of specifi c chromosomal cassettes carrying the mecA gene as well as multiple other genes has provided a new backdrop against which evolution of CNS species and their respective SCCmec can be measured (Mongkolrattanothai et al 2004; Noto and Archer 2006) . A dichotomy between methicillin-susceptible CNS (MSCNS) and MRCNS permeates the literature on susceptibility testing. In fact, these groups are usually tested and reported separately. For example the analysis of US key bloodstream bacterial isolates from 1995, 1996, and 1997 showed that among 43,789 CNS, 42% were MSCNS and 58% were MRCNS (Sahm et al 1999) . Moreover, in this group of MRCNS the rate of vancomycin minimum inhibitory concentration (MIC) of 4 µg/mL increased from 1.8% to 4.8% from 1995 to 1997.
That database, SENTRY, was expanded to other countries during 1997 -1999 (Diekema 2001 . Interestingly, while rates of methicillin resistance among CNS varied widely among 13 European countries, the rate was around 70% for 5 global locations; Canada, USA, Latin America, Europe, and the West Pacific. Co-resistance patterns were also reported for the fi ve regions based on oxacillin resistance. For example in the US trimethoprim-sulfamethoxazole (SXT) resistance was about 17% in MSCNS compared with nearly 57% in MRCNS. Similar trends were seen for gentamicin, ciprofl oxacin, clindamycin, and erythromycin both in US and global sites (Diekema et al 2001) . For most antimicrobials, intensive care units (ICUs) tend to show the highest rates of antimicrobial resistance (Fridkin et al 1999) . In a massive study to determine the focus of antibiotic resistance in different areas for over 80 hospitals, the rates of MRCNS were signifi cantly higher in ICU -than in non-ICU patients and were higher in non-ICU patients than in outpatients. These data suggest that the major risk for MRCNS is associated with more complex hospital environments.
A similar large study was conducted in which staphylococci were collected from 20 regional health centers in several countries across Europe, Asia, and Latin America (Sanches et al 2000) . The CNS were divided into methicillin-resistant S. epidermidis (MRSE), methicillin-resistant S. haemolyticus (MRSH), and other MRCNS and their susceptible counterparts. Cross resistance was most common in the methicillin-resistant groups. For example, rates of SXT, ciprofl oxacin, and gentamicin were 64%, 50.5%, and 72.3% respectively. MRSH showed even higher frequencies of cross resistance. These trends in cross resistance among CNS were different than those for MRSA, suggesting that different selection pressures are at work for the two groups.
Another study tested susceptibility of only skin and soft tissue isolates in 283 US hospitals and 301 hospitals in Europe for 9 antimicrobials, including amoxicillinclavulanate, cefotaxime, cetriaxone, ciprofloxacin, erythromycin, gentamicin, levofloxacin, trimethoprim (TMP)/sulfamethoxazole (SMX), and vancomycin. For MSCNS almost all isolates were susceptible to amoxicillinclavulanate, suggesting that clavulanate remains very active against staphylococcal β-lactamase . For the fl uoroquinolones, ciprofl oxacin averaged about 90% susceptibility and, where tested, levofl oxacin was active against slightly more strains. For example, in Italy 83.3% of isolates were susceptible to ciprofl oxacin versus 85.7% for levofl oxacin. Ranges of activity for gentamicin (86.1%-96.4%) and TMP/sulfamethizole (SMZ) (88.1%-92.7%) were active in a similar range. Over 25% of isolates were resistant to erythromycin whereas all isolates were susceptible to vancomycin. For MRCNS the resistance trends were, in general, similar in European and US isolates with some exception. For example, ciprofl oxacin resistance was 65.0%-66.7% across four European countries (France, Germany, Italy, and Spain) versus a range of 38.1%-47.0% in the US. Gentamicin resistance was higher in Europe (range of 50.2%-61.3%) in the US (32.4%). No vancomycin resistance was detected.
Cuevas et al studied the trends of resistance in clinical isolates of CNS in Spain for fi ve periods from 1986 to 2002 (Cuevas et al 2004) . For all years together, 28% of strains were community in origin and 72% were nososcomial. Oxacillin resistance rose steadily from 32.5% in 1986 to 61.3% in 2002. Gentamicin resistance rates peaked in 1994 at 41.4% but dropped to 27.85% in 2002. Most interestingly, ciprofl oxacin resistance rose from 1.1% in 1986 to 44.9% in 2002. Although there was no vancomycin resistance, there was one isolate in the 1996 study resistant to teichoplanin, an observation made earlier in one isolate of S. epidermidis from a corneal infection (Pinna et al 1999) . Nosocomial strains were more likely to demonstrate resistance. In another study done in Uppsala, Sweden to determine more specifi cally how an ICU stay would infl uence CNS resistance, high rates of oxacillin and ciprofl oxacin resistance (92% and 83% respectively) in 20 ICU patients were correlated with longer lengths of stay. Genotyping of the ICU CNS isolates found 32 pulse fi eld types involved, but 16 genotypes colonized more than 1 individual suggesting some clonality among these CNS isolates.
In a study from Greece of intravenous catheter infections associated with bacteremia, over a 2-year period CNS were responsible for nearly 60% of infections (Paragioudaki et al 2004) . For these pathogens, in 1999, the resistance rate was 72% for ampicillin, oxacillin, ceftazidime, ceftriaxone, cefaclor, amoxicillin/clavulanate, and impenem, with slightly lower rates for SXT, ciprofl oxacin, and amikacin. There was no vancomycin resistance. Rates dropped slightly in the year 2000 for the same antimicrobials. The redundancy of resistance rates may be due to spread of virulent CNS clones as was observed earlier at the University of Patras (Spiliopoulou et al 2003) .
Several studies combined automated species identifi cation with antimicrobial susceptibility testing. From Italy, Ariciola et al reported resistance levels in 15 species of 193 isolates found to colonize orthopedic implants (Arciola et al 2006) . In the 5 most prevalent species -S. hominis, S. haemolyticus, S. capitis, S. warnerii, S. cohenii -resistance to penicillin was similar (51%-66%). Most oxacillin resistance was seen in S. haemolyticus whereas no oxacillin resistance was present in S. warneri. Multiple antibiotic resistance genes were most likely to be found in S. haemolyticus, averaging 2.8 for that species. Though the data are small in number, this study suggests that both careful susceptibility testing along with species identifi cation is helpful in certain device-related infections.
CNS remain the major cause of postcataract endophthalmitis. Recchia et al found that nearly 60% of pathogens from such cases were CNS and 91% of these were S. epidermidis (Recchia et al 2006) . In analyzing 2 groups, for the 5 years before and after 1994, a signifi cant increase in resistance was seen for ciprofl oxacin (20 to 38%) and cefazolin (19 to 40%). TMP/SMZ resistance stated relative stable, around 27%.
The study of device-related antimicrobial resistance has been hampered by lack of good models. Work with newer models has determined activity of various antibacterial solutions activity against different bacteria after adherence to silicone catheter segments (Sherertz et al 2006) . Results showed that S. epidermidis was the most susceptible in terms of log kill over 24 hours to most antimicrobials tested and, in particular, to a complex solution of minocycline, EDTA, and ethanol.
New individual agents
Several new antimicrobials with good anti-staphylococcal activity have been marketed recently or will likely soon be marketed: ceftobiprole, dalbavancin, daptomycin, linezolide, tigecycline and telavancin. We will discuss the reports that have included CNS in the susceptibility profi le.
Linezolid
This oxazolidinone was introduced into clinical practice (in the US) in 2000. Its mechanism of action involves the binding of N-formylmethionyl-tRNA to the ribosome with the 50s subunit, but not the 30s subunit of the ribosome (Shinabarer 1999). There are no comparative trials of linezolid therapy for CNS infections. With an MIC 90 = 1-4 µg/mL, it has become a major option for therapy in resistant and recalcitrant staphylococcal infections including those due to CNS (Davidson and Low 2004) . In the largest in vitro experience as of its 1999 publication, Noskin et al studied 365 oxacillin-susceptible and 441 oxcillin-resistant CNS (Noskin et al 1999) . Both groups had the same MIC 50 and MIC 90 , 2 and 4 µg/mL respectively. At that time, only vancomycin of the agents studied was more active. Data submitted for US registration of linezolid showed MIC 90 values of both methicillin-resistant and methicillin-resistant S. epidermidis of 1-4 µg/mL (Pfi zer data on fi le). Postmarketing surveillance programs reported for 870 CNS isolates an MIC 90 of 1 µg/mL (Ross et al 2005) . Only one isolate had an MIC Ͼ 8 µg/mL.
In vitro development of resistance occurs very slowly with serial passage but when it does occur, it is related to two independently isolated point mutations at G2447U and G2576U of the 23S rRNA (Shinabarger 1999) . Resistance in the clinical setting, interestingly, has involved a report of linezolid-resistant CNS (Potoski et al 2006) . The University of Pittsburgh Medical Center experienced this cluster of 25 linezolid-resistant CNS isolates with a single S. epidermidis clone, shown by pulse-fi eld gel 
Tigecycline
Tigecycline is a minocycline derivitative with excellent activity against resistant Gram-positive bacteria. A South American study analyzed 47 MSCNS and 180 MRCNS for tigecycline susceptibility (Gales et al 2005) . Both groups displayed an MIC 90 of 0.5 µg/mL (identical for S. aureus) and 100% were susceptible to 2 µg/mL. In a 2004 publication 321 MSCNS and 1111 MRCNS mirrored Gales study with MIC 90 of 0.5 µg/mL for both groups (Frische et al 2004) . In a larger study of 3574 CNS, Sader et al found tigecycline exhibited excellent activity against blood stream pathogens . Again the demonstrated MIC 90 was 0.5 µg/mL for CNS and for S. aureus. Data supporting this level of activity were also derived in another study comparing the activity of a new quinolone, DX-619, with other Gram-positive agents (Bogdanovich et al 2005b) . The MIC 90 of tigecycline for 61 MRCNS and 67 MSCNS was 0.5 µg/mL. DX-619 comparatively had an MIC 90 0.06 µg/mL. In another study, limited number of glycopeptide-intermediate susceptible isolated of CNS (22) have been studied for tigecycline and daptomycin susceptibility. In one small set of 8 S. epidermidis isolates and 4 S. haemolyticus isolates, the MIC was again 0.5 µg/mL for tigecycline, 2.0 µg/mL for arbekacin and 1.0 µg/mL for daptomycin (LaPlante and Rybak 2004) . The minimum bactericidal concentration (MBC):MIC ratio was 4 (no specifi cs given). Time-kill experiments for tetracycline at 4 times the MIC against glycopeptide-intermediate S. epidermidis revealed similar killing to daptomycin but signifi cantly more activity than vancomycin at 24 hours. Thus, as a tetracycline derivative, tigecycline is surprisingly active against susceptible and resistant CNS and has some bactericidal effect.
Daptomycin
Daptomycin, an older cyclic glycopeptide that had been studied for several decades, was recently brought back to clinical life. It made its clinical debut in 2003 for approved use in skin and soft tissue infection and has been shown recently to be clinically non-inferior to vancomycin in clinical trials of staphylococcal bacteremia (Fowler et al 2006) . Daptomycin probably has several mechanisms of action that involve perturbation of calcium-dependent channels to disrupt the cytoplasmic membrane, perhaps fi rst by altering the membrane potential (Silverman et al 2001; Friedman et al 2006) . One of the largest studies of daptomycin-CNS interactions consisted of 1126 CNS (as verifi ed by Vitek coagulase testing) taken from 6,973 gram-positive isolates collected from patient specimens at 50 hospitals distributed throughout the nine US Bureau of the Census regions (Critchley et al 2003) . Daptomycin was consistently active with an MIC range of 0.015-2.0 µg/mL and an MIC 90 of 0.5 µg/mL. Daptomycin and quinupristin/dalfopristin were the most active agents seen in this analysis. As an anti-staphylococcal agent, daptomycin may have other advantages like a very low spontaneous resistance rates seen during serial passage, and the fact that resistant mutants had lower virulence in an animal model (Silverman et al 2001) . When daptomycin was tested for in vitro activity in Mueller-Hinton broth supplemented with 50 mg of calcium per liter, MICs were about 4-fold lower (Petersen et al 2002) . In a comparative study against tigecycline, and other Gram-positive agents, the MIC 90 of daptomycin and tigecycline for MSCNS was 0.25 µg/mL and 0.5 µg/mL respectively but was 8-and 2-fold higher for MRCNS, respectively. In comparison, the MIC rose multifold for other agents like erythromycin, levofl oxacin, and teicoplanin. Resistance to daptomycin has been shown in the laboratory with serial passage. Elegant experiments of genome comparison revealed that the non-susceptible mutants were altered in MprF, a lysylphosphatidylglycerol synthetase (Silverman et al 2006) .
New fl uoroquinolones
Several new quinolones have excellent activity against CNS. As stated above (see daptomycin), a des-F(6)-quinolone, DX-619 was compared to 6 other quinolones. For strains that had an MIC 90 of 16.0 µg/mL, the DX-619 MIC 90 was 0.125 µg/mL, one tube lower than another new quinolone agent, sitafl oxacin (Bogdanovich et al 2005b) . Interestingly, killing for DX-619 of a vancomycin-nonsusceptible CNS was complete at 4 × MIC and Ͼlog4 at 12 hours for 2 × MIC. Of the currently used fl uoroquinolones, moxifl oxacin is probably the most frequently used. Its MIC 90 for MSCNS was 1.0 µg/mL and for MRCNS was MSCNS was 4.0 µg/mL.
New cephalosporins
Historically, β-lactam antibiotics have produced excellent results against methicillin-susceptibile staphylococci. Production of aberrant penicillin-binding proteins like PBP-2A bypass the effect of β-lactams. Thus, there has been a search to fi nd β-lactams that themselves bind to PBP-2A and thus render strains susceptible. Ceftobiprole is one of a new group of cephalosporins that are active against methicillin-resistant staphylococci. MRSA are susceptible to ceftobiprole at an MIC 50 /MIC 90 of 2/2 and MRCNS are similarly susceptible with a range of 0.125-4 µg/mL (Bogdanovich et al 2005a) . Ceftobiprole also demonstrates excellent time-kill kinetics and in S. aureus a good post-antibiotic effect (PAE) at MIC and sub-MIC concentrations (Pankuch and Applebaum 2006) . In a study of isolates from diabetic foot infections, staphylococci were speciated and had excellent ceftibiprole MIC 90 values (µg/mL): methicillin-susceptible S. aureus (MSSA), 0.5; MRSA 1.0; S. epidermidis 1.0; S. haemolyticus 2.0, and S. ludgenensis 0.5.
New glycopeptides
Several derivatives of vancomycin have been developed and brought to clinical trials. Telavancin is a rapidly bactericidal lipoglycopeptide with excellent staphylococcal activity. In a study of telavancin versus standard therapy for treatment of skin and soft tissue infection, CNS caused 13 of 122 staphylococcal infections (Stryjewski et al 2006) . The MIC 90 for telavancin was 0.25 µg/mL (0.06-0.25) among CNS isolates that had a MIC 90 of 2.0 for oxacillin. Televancin also is one of the few newer agents to exhibit activity in biofi lms (Gander et al 2005) . A 3-log decrease in 2 CNS isolates was demonstrated in a so-called Sorbarod biofi lm model.
Dalbavancin is another lipoglycopeptide that inhibits cell-wall synthesis. In a British study of 92 isolates from 60 hospital laboratories, 100% of the isolates were inhibited by 1 µg/mL of drug (Mushtaq et al 2004) . The E-test MIC correlation was excellent with broth dilution but less correlation with agar dilution methodology (Fritsche et al 2006) . In another study of dalbavancin compared to other agents including oritavancin, an experimental glycopeptide, dalbavancin had exceptional activity at the MIC 90 level (0.06 µg/mL) for both MSCNS and MRCNS (King et al 2004) . In that study, ortivancin had an MIC 90 of 2.0 µg/mL and 4.0 µg/mL for MSCNS and MRCNS. Interestingly, dalbavancin has a very long half-life (7.5 days) that, when marketed, will challenge prescribers who are used to much shorter dosing intervals.
Other agents
Other agents are on the Gram-positive therapy horizon, but very few have shown enough promise to come to clinical trials. One agent, API-1252, from a group called enoyl-acyl carrier protein reductases, has shown excellent antistaphylococcal activity. The MICs for S. epidermidis isolates from Canada to API-1252 were excellent, with MIC 90 for methicillin-suscetible S. epidermidis (MSSE) and MRSE of 0.06 and 0.03 µg/mL respectively, only slightly higher than the MIC 90 s for S. aureus (Karlowsky et al 2007) . A second group worth mentioning are the acyldepsipeptides (ADEPs) which have a unique mechanism of action and are quite active against Gram-positive bacteria. ADEPs activate the protease function of ClpP proteins to cause a dysregulation of proteolysis (Brötz-Osterhelt et al 2005) . The MIC 50 for S. aureus of one ADEP, is as low as 0.05 µg/mL, but data for CNS have yet to be published.
The effect of staphylococcal biofi lm on antimicrobial susceptibility
Biofi lms consists of a complex extracellular matrix that can have profound effects on the ability of antimicrobials to inhibit and kill bacteria and fungi. Biofi lms are extremely common in infections due to CNS, bacteria that have special sets of genes that regulate and determine cell-wall associated adhesion and biofi lm production (Mack et al 2006) . The regulation of biofi lm production for most staphylococci involves complex schemes (agr, sar, sigB) that result in sets of genes being turned on and off depending on the current cellular environment. Biofi lm regulation involves up and down regulation of genes that mediate information storage, cellular processes and signaling, metabolism and other functions (Yao et al 2006) .
It has been known several years that biofi lms interact with antimicrobials (Khardori et al 1991) . Early work suggested that subtherapeutic levels of certain agents like fluoroquinolones and glycopeptides would not prevent attachment of bacteria but that β-lactam agents and vancomycin could inhibit aggregative activity (Rupp and Hamer 1998) . The mechanism of biofi lm-associated antimicrobial resistance is likely multifactorial. Unlike other methods to test antimicrobial susceptibility, methods that address biofi lm susceptibility to antimicrobial agents have been needed to defi ne fully the infl uence of biofi lm on susceptibility (Patel 2005) . To that end, very recent work comparing planktonic bacteria to biofi lm-grown ones has shown large differences in susceptibility. Almost all single agents studied (linezolid, cefazolin, oxacillin, vancomycin, gentamicin, azithromycin, ciprofl oxacin and fusidic acid) had a marked increase in the MBC versus the MIC using what is called a modifi cation of the Calgary Biofi lm Device (Saginur et al 2006) . Rifampin alone had some predictable equivalence between the MIC and the MBC. For S. epidermidis isolates, certain combinations, almost always containing rifampin, were bactericidal against Ն90% of biofi lms (examples rifampin/vancomycin/ gentamicin; rifampicin/ciprofloxacin/fusidic acid), but a smaller number of antibiotic combinations were active against biofi lm-grown bacteria than against planktonic bacteria. Strains of S. lugdenensis in biofi lm have been shown to be particularly susceptible to moxifl oxacin, suggesting that some fl uoroquinolones do have good biofi lm activity (Frank et al 2007) . In the same model, vancomycin was shown to be non-bactericidal, thus suggesting that biofi lm contributes to the phenomenon of tolerance or lack of killing in certain glycopeptides.
The effects of antimicrobials seem to be different at the time of adherence versus the later stage of mature biofi lm formation. In a study to test interaction of specifi c agents with biofi lm, dicloxacillin was more active at both stages than cefazolin and vancomycin. Finally, biofi lm susceptibility may be staphylococcal species specifi c (Cerca et al 2005) . An Argentine study looked at 5 CNS species and found that of 88 biofi lm producing strains, resistance to 2 or more agents was seen in 29% of S. haemolyticus, 24% of S. saprophyticus, and 20% of S. epidermidis (Gaudioso de Allori et al 2006) . Such work implies that rapid evaluation of biofi lm-associated resistance should be integrated into clinical consideration. Furthermore, their in vitro fi ndings can be translated into clinically applicable devices.
Tigecycline and N-acetylcysteine have been embedded into vascular catheters. Such combinations are not only inhibitory of biofi lm growth in vitro but also act synergistically against MRSA and MRSE (Aslam et al 2007) .
Concluding remarks
Coagulase negative staphylococci comprise many species which have become increasing pathogenic to man by virtue of a changing host of demographics. CNS are relatively more resistant than their S. aureus counterparts but have fewer virulence factors. They do have a penchant for forming biofi lms on device materials and devitalized tissue, making biofi lm-associated CNS more resistant to penetration by antimicrobial agents. There are now good methods to show that biofi lms markedly increase the inhibitory concentration of standard antistaphylococcal agents. Hospital CNS have broad spectrum resistance and usually carry SCCmec cassettes that make their host resistant not only to β-lactam but a wide array of currently available antimicrobials. There are several newly marketed agents including linezolid, tigecycline, and daptomycin that have excellent activity against CNS including one species that is almost always pathogenic, S. lugdenesis. Other new, non-marketed agents including variations on vancomycin and new peptide agents show promise in vitro. Like their forebearers, however, there is always the spectre of evolving resistance, and only time will determine how rapidly resistance does emerge in the clinical arena.
